Evaluating reference-based pricing initial findings and prospects

摘要: Reference-based pricing is a controversial policy mechanism used to control pharmaceutical expenditures. After its implementation in some European countries, the British Columbia government introduced version of reference-based October 1995. The authors reviewed previous studies other countries and conducted preliminary assessment impacts BC system by analysing secondary utilization cost data. introduction jurisdictions within Organisation for Economic Cooperation Development, there was temporary reduction rate growth total expenditures, followed return trends subsequent years. Similarly, initial data from showed dramatic declines annual expenditures drugs referenced categories (from $42.0 million year before $23.7 after). Although early evidence suggests that indeed reducing drug much more research needed make final determination success. A comprehensive longitudinal evaluation should take into account wide range non-cost impacts, most important which are effects on health outcomes.